Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium Ga 68 N188
- Development stage
- Phase 1
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
Gallium Ga 68 N188 is a radiopharmaceutical composed of a nectin-4-targeting bicyclic peptide (N188) labeled with the positron-emitting radioisotope gallium-68. It is designed for use in PET/CT imaging to noninvasively quantify membranous nectin-4 expression in tumors. The agent binds specifically to nectin-4 (poliovirus receptor-like protein 4; PVRL4), an emerging biomarker overexpressed in several cancers including urothelial carcinoma, pancreatic cancer, intrahepatic cholangiocarcinoma, cervical cancer, and hepatocellular carcinoma. By visualizing and quantifying nectin-4 expression levels in vivo, [68Ga]N188 can help stratify patients for therapies targeting nectin-4 (such as enfortumab vedotin) and may assist with staging or restaging disease. Preclinical and clinical studies have demonstrated high affinity for nectin-4 and favorable pharmacokinetics and safety profiles[1][2][5][4].
- Other names
- gallium Ga-68 N188[^68Ga]N188
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on gallium Ga 68 N188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium Ga 68 N188.